4D Molecular Therapeutics Files 8-K with Board and Compensation Updates
Ticker: FDMT · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
TL;DR
4D Molecular Therapeutics filed an 8-K on 9/30/25 covering board changes, executive pay, and corporate amendments.
AI Summary
On September 30, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes amendments to its articles of incorporation or bylaws and financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's governance and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is routine and reports on corporate governance and administrative matters, not significant financial distress or operational changes.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates a departure of directors and the election of new directors, but the specific names and details are not provided in this excerpt.
What are the key aspects of the compensatory arrangements for certain officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not elaborated upon in this excerpt.
Were there any amendments to the company's articles of incorporation or bylaws?
Yes, the filing states that there were amendments to the articles of incorporation or bylaws.
What type of financial statements were included in the filing?
The filing indicates that financial statements and exhibits were included, but the specific nature or period covered by these statements is not detailed in this excerpt.
What is the primary business of 4D Molecular Therapeutics, Inc.?
4D Molecular Therapeutics, Inc. is involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2025-10-02 16:04:49
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FDMT Nasdaq Glo
Filing Documents
- fdmt-20250930.htm (8-K) — 50KB
- fdmt-ex3_1.htm (EX-3.1) — 343KB
- 0001193125-25-228289.txt ( ) — 550KB
- fdmt-20250930.xsd (EX-101.SCH) — 26KB
- fdmt-20250930_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 30, 2025, the Board amended and restated the Company's current amended and restated bylaws (the "Amended and Restated Bylaws"). The Amended and Restated Bylaws were amended to, among other revisions, update the advance notice procedures for business brought before a meeting and update the advance notice procedures for nominations of directors. The foregoing summary and description of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is filed as Exhibit 3.1 with this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 3.1 Amended and Restated Bylaws 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: October 2, 2025 By: /s/Scott Bizily Scott Bizily Chief Legal Officer